Nyxoah SA（NYXH）の株式分析

AI分析 of Nyxoah SA (NYXH)

中立

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.

バリュエーション指標

Nyxoah SA（NYXH）の現在の予想PERは0.00で、5年平均は-4.19です。

予想PER

割高

5年平均 P/E

-4.19

現在のP/E

0.00

割高

-0.85

割安

-7.52

予想EV/EBITDA

適正

5年平均 EV/EBITDA

-3.12

現在のEV/EBITDA

-0.42

割高

-0.25

割安

-5.99

予想PSR

適正

5年平均 P/S

23.23

現在のP/S

1.26

割高

45.85

割安

0.61

Alphio AI による NYXH の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。

強

強気

強気 · 25%NYXH

$9.24

シナリオ価格

基

基本

基本 · 50%NYXH

$7.86

シナリオ価格

弱

弱気

弱気 · 25%NYXH

$7.48

シナリオ価格

NYXH を保有するクジラ

P

Pentwater Capital Management LP

+ を保有NYXH

-3.88%

3か月リターン

NYXH のよくある質問 — Alphio AI が回答

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.